CureSign
Monitoring Cancer Treatment Efficacy
Company Overview
Snapshot
Founded in February 2019 by Yakir Rottenberg, CureSign operates with 1–10 employees. The company has secured funding across one disclosed round from two investors, including Peregrine Ventures. CureSign ceased operations in February 2023.
Business overview
CureSign is a medical device company focused on revolutionizing cancer treatment. The company's core technology integrates sensors with advanced signal processing and big data tools to develop a product designed to enable clinical teams to tailor patient-specific treatments for cancer patients. CureSign operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Digital Healthcare markets with a focus on Medical Treatment & Therapeutics and Medical Decision Support.
Log in to access full profile ›Company Intelligence Q&A
- What is CureSign's primary focus?
- CureSign is a medical device company aiming to disrupt how oncologists treat cancer patients by monitoring cancer treatment efficacy.
- When was CureSign founded?
- CureSign was founded in February 2019.
- Who is a key founder of CureSign?
- Yakir Rottenberg is a co-founder, inventor, and medical director at CureSign.
- What is the status of CureSign's operations?
- CureSign ceased to operate in February 2023.
- Which investors participated in CureSign's funding round?
- In February 2020, CureSign received funding from investors including Peregrine Ventures.